HALO
Halozyme Therapeutics Inc
NASDAQ: HALO · HEALTHCARE · BIOTECHNOLOGY
$63.06
-1.25% today
Updated 2026-04-29
Market cap
$7.47B
P/E ratio
24.63
P/S ratio
5.35x
EPS (TTM)
$2.56
Dividend yield
—
52W range
$48 – $82
Volume
1.6M
Halozyme Therapeutics Inc (HALO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
22.70%
Operating margin
56.30%
ROE
153.60%
ROA
22.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $981746.00 | $-14.75M | 55.49% | -1,587.26% | -1,502.63% |
| 2007 | $3.80M | $-23.90M | 93.67% | -740.89% | -628.93% |
| 2008 | $8.76M | $-48.65M | 96.21% | -575.47% | -555.15% |
| 2009 | $13.67M | $-58.36M | 97.72% | -427.60% | -426.88% |
| 2010 | $13.62M | $-53.24M | 92.77% | -398.25% | -390.79% |
| 2011 | $56.09M | $-19.77M | 99.54% | -35.37% | -35.25% |
| 2012 | $42.33M | $-53.55M | 97.41% | -126.70% | -126.53% |
| 2013 | $54.80M | $-83.48M | 88.60% | -146.78% | -152.33% |
| 2014 | $75.33M | $-68.38M | 69.83% | -83.68% | -90.76% |
| 2015 | $135.06M | $-32.23M | 78.35% | -20.33% | -23.86% |
| 2016 | $146.69M | $-103.02M | 77.36% | -56.72% | -70.23% |
| 2017 | $316.61M | $62.97M | 90.16% | 25.58% | 19.89% |
| 2018 | $151.86M | $-80.33M | 93.33% | -45.65% | -52.90% |
| 2019 | $195.99M | $-72.24M | 76.76% | -34.50% | -36.86% |
| 2020 | $267.59M | $129.09M | 83.79% | 53.91% | 48.24% |
| 2021 | $443.31M | $402.71M | 81.64% | 62.24% | 90.84% |
| 2022 | $660.12M | $202.13M | 78.90% | 40.53% | 30.62% |
| 2023 | $829.25M | $281.59M | 76.80% | 40.71% | 33.96% |
| 2024 | $1.02B | $444.09M | 84.30% | 54.32% | 43.74% |
| 2025 | $1.40B | $316.89M | 78.13% | 58.45% | 22.69% |